AusBiotech has announced the appointment of Dr Dell Kingsford Smith to its board of directors.
Dr Kingsford Smith joins the AusBiotech board with more than 20 years of experience in clinical and commercial strategy across medical technology, pharmaceuticals, and vaccines.
She recently served as AusBiotech’s 2024 board observer and currently heads medical affairs, market access, and government affairs for Cochlear.
Before joining Cochlear, Dr Kingsford Smith spent more than a decade with Janssen in local and global leadership roles spanning market access, pricing, and commercial strategy.
Dr Kingsford Smith said, “I am honoured to have the trust and support of the AusBiotech membership in being elected to the Board. I look forward to working across the broad range of Australian biotech and medtech stakeholders to further strengthen and grow this vital, innovative sector of our economy.”
AusBiotech’s chair, Dr James Campbell, said, "On behalf of AusBiotech, I am pleased to welcome Dr Dell Kingsford Smith to our Board. Not only does she bring invaluable expertise from discovery to commercialisation, but also an unwavering passion for improving patient access. Her outstanding track record across the life sciences sector makes her an exceptional addition to the Board.”
AusBiotech CEO Rebekah Cassidy added, “I’m delighted that our members have chosen Dell to join our Board and am honoured to work alongside such a diversely experienced set of sector leaders. Their collective expertise and commitment support our organisation's clear and forward-thinking direction. Dell’s extensive knowledge and experience will provide crucial support in fostering the growth of our members and advancing Australia's thriving life sciences ecosystem.”